Abstract: Novel quinazoline and cinnoline derivatives having the formula ##STR1## (wherein one of A and B is CH and the other one of A and B is N; X.sub.1 is halogen or CF.sub.3 and X.sub.3 is one of the groups II, III, IV or V ##STR2## where Q is lower alkylene; R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.3 are independently lower alkyl or R.sub.2 and R.sub.3 are a divalent radical such that HNR.sub.2 R.sub.3 is a secondary cyclic amine with 5 to 7 ring atoms; R.sub.4 is lower alkyl; n is 0 or 1; the rings shown in formulae III and IV are piperidine or pyrrolidine optionally substituted by lower alkyl; and the ring shown in formula V is piperazine optionally substituted by lower alkyl) and their pharmaceutically acceptable salts are useful as pharmaceuticals particularly as anti-hypertensives. Novel intermediates are also described including the corresponding sulphonic acids of formula I ( (where A, B and X.sub.1 are defined above and X.sub.3 is OH).

Abstract: New compounds having the formula I ##STR1## where one of A and B is CH or N, the other of A and B is CH, Q is lower alkylene, R is lower alkyl, X.sub.1 is halogen or trifluoromethyl and X.sub.2 and X.sub.3 are independently selected from hydrogen, halogen, trifluoromethyl, lower alkoxy and lower alkyl and the pharmaceutically acceptable acid additions are disclosed as anti-hypertensive agents. New compounds having the formula II ##STR2## where Q, R, X.sub.2 and X.sub.3 are as explained above and n is 0 or 1 and their acid addition salts are useful as intermediates.

Abstract: Novel quinazoline and cinnoline derivatives having the formula ##STR1## (wherein one of A and B is CH and the other one of A and B is N; X.sub.1 is halogen or CF.sub.3 and X.sub.3 is one of the groups II, III, IV or V ##STR2## where Q is lower alkylene; R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.3 are independently lower alkyl or R.sub.2 and R.sub.3 are a divalent radical such that HNR.sub.2 R.sub.3 is a secondary cyclic amine with 5 to 7 ring atoms; R.sub.4 is lower alkyl; n is 0 or 1; the rings shown in formulae III and IV are piperidine or pyrrolidine optionally substituted by lower alkyl; and the ring shown in formula V is piperazine optionally substituted by lower alkyl) and their pharmaceutically acceptable salts are useful as pharmaceuticals particularly as anti-hypertensives. Novel intermediates are also described including the corresponding sulphonic acids of formula I (where A, B and X.sub.1 are defined above and X.sub.3 is OH).

Abstract: Compounds having the formula ##STR1## wherein X.sub.1 and X.sub.2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy; X.sub.3 is halogen or trifluoromethyl; one of A and B is CH and the other is CH or N and their pharmaceutically acceptable acid addition salts are useful as pharmaceuticals, in particular as anti-hypertensive agents. Novel 1-[4-(amino or nitro)benzenesulphonyl]-4-benzoylpiperazines are also disclosed as intermediate compounds.

Abstract: 4-Aminoquioline derivatives having the formula ##STR1## and their pharmaceutically acceptable salts where X.sub.1 is halogen or trifluoromethyl and X.sub.2 is a group having the formula--NR.sub.1 --Q--N--R.sub.4 (II)where R.sub.1 is hydrogen or lower alkyl; Q is lower alkylene; R.sub.4 is lower alkyl and the ring illustrated is a piperidine or pyrrolidine ring optionally substituted by lower alkyl, exhibit anti-hypertensive activity. Corresponding compounds where R.sub.4 is replaced by latent lower alkyl, a protecting group or hydrogen may be used as intermediates.

Abstract: Compounds having the formula ##STR1## wherein X.sub.1 and X.sub.2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy; X.sub.3 is halogen or trifluoromethyl; one of A and E is CH and the other is CH or N and their pharmaceutically acceptable acid addition salts are useful as pharmaceuticals, in particular as anti-hypertensive agents. Novel 1-[4-(amino or nitro)benzenesulphonyl]-4-benzoylpiperazines are also disclosed as intermediate compounds.

Abstract: Novel quinazoline and cinnoline derivatives having the formula ##STR1## (wherein one of A and B is CH and the other one of A and B is N; X.sub.1 is halogen or CF.sub.3 and X.sub.3 is one of the groups II, III, IV or V ##STR2## where Q is lower alkylene; R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.3 are independently lower alkyl or R.sub.2 and R.sub.3 are a divalent radical such that HNR.sub.2 R.sub.3 is a secondary cyclic amine with 5 to 7 ring atoms; R.sub.4 is lower alkyl; n is 0 or 1; the rings shown in formulae III and IV are piperidine or pyrrolidine optionally substituted by lower alkyl; and the ring shown in formula V is piperazine optionally substituted by lower alkyl) and their pharmaceutically acceptable salts are useful as pharmaceuticals particularly as anti-hypertensives. Novel intermediates are also described including the corresponding sulphonic acids of formula I (where A, B and X.sub.1 are defined above and X.sub.3 is OH).

Abstract: Compounds containing a cation of formula Ia ##STR1## and a pharmaceutically acceptable anion are anti-fungal agents. In formula Ia and Ib R.sub.1 is alkyl of at least 3 carbon atoms or aralkyl; R.sub.2 and R.sub.5 are hydrogen, lower alkyl, lower alkoxy, halogen or nitro; R.sub.6 and R.sub.7, when separate, are lower alkyl or aryl(lower)alkyl or, when joined together, are --(CH.sub.2).sub.2 --A--(CH.sub.2).sub.2 -- (where A is --(CH.sub.2).sub.n --, O, S or NR.sub.8 where n is O, 1 or 2 and R.sub.8 is lower alkyl) or a mono- or di-(lower alkyl) substitution product thereof.

Abstract: Thiazolotriazine derivatives having the formula I ##STR1## their pharmaceutically acceptable salts, pharmaceutically acceptable triazolotriazinium compounds containing the cation having formula II ##STR2## and their zwitterionic forms and pharmaceutically acceptable acid addition salts [where A is hydroxy whilst B is hydrogen or A and B together represent a direct bond; R.sup.1 is aryl; R.sup.2 and R.sup.3 are independently lower alkyl or ar(lower)alkyl] are novel compounds useful as anti-cancer agents.

Abstract: The disclosure describes new 4-aminoquinoline derivatives of general formula ##STR1## and their pharmaceutically acceptable acid addition salts, where X is trifluoromethyl or halogen, Z is hydrogen or a defined substituent and R is a group having one of the formulae ##STR2## where R.sup.1 is hydrogen or lower alkyl, R.sup.2 is lower alkyl, R.sup.3 is lower alkyl and A is lower alkylene. The new 4-aminoquinoline derivatives show analgesic activity and, in some cases, anti-inflammatory activity.

Abstract: New 4-aminoquinoline derivatives having the formula ##STR1## wherein X is halogen or trifluoromethyl at the designated 7- or 8-position; Z is hydrogen, halogen, lower alkyl, lower alkoxy, nitro, di(lower alkyl)amino or trifluoromethyl, n is from 1 to 4, R.sup.1 is hydrogen or lower alkyl, R.sup.2 is lower alkyl, R.sup.3 is lower alkyl and A is lower alkylene, and their pharmaceutically acceptable acid addition salts show anti-inflammatory activity.

Abstract: 4-Aryl-4-hydroxythiazolines can be obtained by treatment of aroylmethyl bromides with thiourea or a N-(lower alkyl)thiourea. The hydroxythiazolines are believed to have the formula ##STR1## where Ar is aryl and R is hydrogen or lower alkyl. The compounds are also capable of existing in open chain tautomeric form. The compounds show anti-ulcer activity in mammals.

Abstract: New thiazolotriazines having the formula ##STR1## (where R.sup.1 is aryl and R.sup.2 is ar(lower)alkyl, lower alkyl or lower alkenyl) and their pharmaceutically acceptable acid addition salts are described. The corresponding thiazolotriazinium compounds comprising a cation having the formula ##STR2## (where R.sup.1 and R.sup.2 are as explained above and R.sup.3 is ar(lower)alkyl, lower alkyl or lower alkenyl) and a pharmaceutically acceptable anion are also described. The compounds are indicated for use as anti-ulcer agents.